Silence Therapeutics
UK biotech co. discovering molecules with RNA tech to target genes in diseases with unmet needs.
UK biotech co. discovering molecules with RNA tech to target genes in diseases with unmet needs.
Silence Therapeutics, founded in the UK, is a biotechnology company dedicated to transforming lives by developing precision-engineered medicines using RNA technology. Their core mission is to silence diseases through the design and development of short interfering RNAs (siRNAs), targeting specific genes involved in the pathology of diseases with significant unmet medical needs. The company focuses on creating novel therapeutic molecules to address conditions for which current treatment options are limited or inadequate.
Notable figures associated with Silence Therapeutics include a team of pioneering scientists and experienced biotech professionals. The company has garnered attention from prominent investors in the biotech sector, contributing to its growth and innovation. Key achievements include advancing a new generation of siRNA-based medicines and making significant strides in clinical trials. Overall, Silence Therapeutics has had a substantial impact on the field of RNA interference (RNAi) therapeutics, offering hope to patients with previously untreatable conditions.
Companies similar to Silence Therapeutics include Alnylam Pharmaceuticals aln, Sirnaomics, Silvec Biologics and Tacit Therapeutics.
Silence Therapeutics was founded in 1994.
Silence Therapeutics' headquarters is located in London, Greater London, GB.
Silence Therapeutics' most recent funding round was for $120M (USD) in February 2024.
As of Feb 5, 2024, Silence Therapeutics has disclosed funding of $248.7M (USD). Undisclosed round amounts are excluded.
Silence Therapeutics has 120 employees as of Feb 12, 2024.
Tacit Therapeutics
tacittx.com
